AbbVie (NYSE:ABBV) is a global biopharmaceutical company that specializes in the discovery, development, manufacturing, and marketing of advanced medicines.
AbbVie focuses primarily on immunology, oncology, neuroscience, and virology treatments, and it has a broad portfolio of prescription drugs aimed at addressing a range of medical conditions.
Humira (adalimumab), one of the world's best-selling drugs, used to treat various autoimmune conditions. However, Humira's patent expired in 2023, and AbbVie has been transitioning to a newer drug, Rinvoq in this space.
AbbVie develops treatments for various cancers, focuses on treatments for neurological and psychiatric conditions. 2 very popular drugs, (Allergan and Botox (botulinum toxin) have various medical and aesthetic uses. 
The chart is fascinating as the low-risk opportunity to invest in this dividend-paying stock is emerging.
Currently trading under the 50 and 200-DMAs, the phase is distribution.
However, if you look left, you can see that ABBV made a low in November and since, has found some buyers.
The support level of $160 is the risk point.
Real Motion shows a mean reversion to the buyside could be happening.
Plus, the leadership indicator tells us that it is on support.
$172 is pivotal right now in a move and hold above looks compelling for a starter position.
ETF Summary
(Pivotal means short-term bullish above that level and bearish below)
- S&P 500 (SPY) 604 support
- Russell 2000 (IWM) Want to see this get back thru 240
- Dow (DIA) 445 resistance
- Nasdaq (QQQ) 520 support
- Regional banks (KRE) 65 pivotal
- Semiconductors (SMH) 250 cleared, now support with 260 point to clear
- Transportation (IYT) Still weak and into the Fed decision. 68 key support
- Biotechnology (IBB) 140 resistance 130 major support
- Retail (XRT) 80 support 87 resistance
- iShares iBoxx Hi Yd Cor Bond ETF (HYG) 79.50 now the nearest support level